Afuco™ Anti-MS4A1 ADCC Therapeutic Antibody (Tositumomab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Human CD20. Tositumomab is a drug for the treatment of follicular lymphoma. It is an IgG2a anti-CD20 monoclonal antibody derived from immortalized mouse cells. Tositumomab is applied in a sequential infusion followed by iodine (131I) tositumomab, which is the same antibody covalently bound to the radionuclide iodine-131 (131I). 131I emits both beta and gamma radiation and decays with a half-life of 8 days.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-017 |
| Pricing | Inquiry |
| Host | Mouse |
| Target | MS4A1 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | Neut, ELISA, IF, IP, FuncS, FC |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |